- Home
- KYMR vs MRUS Comparison
KYMR vs MRUS Comparison
Compare KYMR & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYMR
- MRUS
- Stock Information
- Founded
- KYMR 2015
- MRUS 2003
- Country
- KYMR United States
- MRUS Netherlands
- Employees
- KYMR N/A
- MRUS N/A
- Industry
- KYMR Medicinal Chemicals and Botanical Products
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- KYMR Health Care
- MRUS Health Care
- Exchange
- KYMR Nasdaq
- MRUS Nasdaq
- Market Cap
- KYMR 2.6B
- MRUS 2.9B
- IPO Year
- KYMR 2020
- MRUS 2016
- Fundamental
- Price
- KYMR $40.61
- MRUS $39.45
- Analyst Decision
- KYMR Buy
- MRUS Strong Buy
- Analyst Count
- KYMR 15
- MRUS 12
- Target Price
- KYMR $55.60
- MRUS $87.92
- AVG Volume (30 Days)
- KYMR 532.1K
- MRUS 706.1K
- Earning Date
- KYMR 02-20-2025
- MRUS 02-26-2025
- Dividend Yield
- KYMR N/A
- MRUS N/A
- EPS Growth
- KYMR N/A
- MRUS N/A
- EPS
- KYMR N/A
- MRUS N/A
- Revenue
- KYMR $87,563,000.00
- MRUS $35,932,000.00
- Revenue This Year
- KYMR N/A
- MRUS N/A
- Revenue Next Year
- KYMR $33.16
- MRUS $57.37
- P/E Ratio
- KYMR N/A
- MRUS N/A
- Revenue Growth
- KYMR 86.92
- MRUS N/A
- 52 Week Low
- KYMR $26.92
- MRUS $31.62
- 52 Week High
- KYMR $53.27
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- KYMR 47.90
- MRUS 38.07
- Support Level
- KYMR $40.20
- MRUS $38.52
- Resistance Level
- KYMR $44.34
- MRUS $47.75
- Average True Range (ATR)
- KYMR 2.58
- MRUS 2.05
- MACD
- KYMR 0.29
- MRUS -0.17
- Stochastic Oscillator
- KYMR 57.47
- MRUS 16.83
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.